Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis.

Slides:

Advertisements

Similar presentations

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis

Advertisements

Frank Vandekerckhove Jaarcongres VVOG Genk, 10 oktober 2013

Yuqian Cui, M. D. , Ph. D. , Yuhua Shi, M. D. , Ph. D. , Linlin Cui, M

Goserelin fosters bone elongation but does not prevent ovarian damage in cyclophosphamide-treated prepubertal mice Laura Detti, M.D., Rebecca A. Uhlmann,

Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study Thi.

Antral follicle count (AFC) can be used in the prediction of ovarian response but cannot predict the oocyte/embryo quality or the in vitro fertilization.

Gonadotropin-releasing hormone agonist trigger increases the number of oocytes and embryos available for cryopreservation in cancer patients undergoing.

Safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole-gonadotropin protocol for fertility preservation.

Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective,

Does the time interval between antimüllerian hormone serum sampling and initiation of ovarian stimulation affect its predictive ability in in vitro fertilization–intracytoplasmic.

Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor.

Mike Ripley, M. D. , F. R. C. S. C. , Andrea Lanes, M. Sc

Janet Kwee, M. D. , Roel Schats, M. D. , Ph. D. , Joseph McDonnell, M

Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm.

Patient-tailored ovarian stimulation for in vitro fertilization

A randomized assessor-blind trial comparing highly purified hMG and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer

Ethnicity as a determinant of ovarian reserve: differences in ovarian aging between Spanish and Indian women Carlos Iglesias, M.D., Manish Banker, M.D.,

Contribution of the rate of change of antimüllerian hormone in estimating time to menopause for late reproductive-age women Ellen W. Freeman, Ph.D.,

Antimüllerian hormone levels and antral follicle count as prognostic indicators in a personalized prediction model of live birth Scott M. Nelson, M.R.C.O.G.,

Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimüllerian hormone–stratified, dose–response trial in women undergoing.

Antimüllerian hormone as a predictor of live birth following assisted reproduction: an analysis of 85,062 fresh and thawed cycles from the Society for.

Antimüllerian hormone levels and antral follicle counts are not reduced compared with community controls in patients with rigorously defined unexplained.

A differential cytokine expression profile is induced by highly purified human menopausal gonadotropin and recombinant follicle-stimulating hormone in.

The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count Simone L. Broer, B.Sc., Ben Willem J.

Biomarkers of ovarian response: current and future applications

Anti-Müllerian hormone: correlation of early follicular, ovulatory and midluteal levels with ovarian response and cycle outcome in intracytoplasmic sperm.

Mikkel Rosendahl, M. D. , Claus Yding Andersen, D. M. Sc

A Markov model of the cost-effectiveness of human-derived follicle-stimulating hormone (FSH) versus recombinant FSH using comparative clinical trial data

Improved monofollicular ovulation in anovulatory or oligo-ovulatory women after a low- dose step-up protocol with weekly increments of 25 international.

Evaluating the performance of serum antimullerian hormone concentration in predicting the live birth rate of controlled ovarian stimulation and intrauterine.

Differences in gene expression of granulosa cells from women undergoing controlled ovarian hyperstimulation with either recombinant follicle-stimulating.

Chao-Chin Hsu, M. D. , Ph. D. , Hsin-Chih Kuo, Ph. D

Evaluation of serum antimullerian hormone and inhibin B concentrations in the differential diagnosis of secondary oligoamenorrhea Hang Wun Raymond Li,

Albert Hsu, M. D. , Margaret Arny, Ph. D. , Alexander B. Knee, M. S

Microdose flare protocol with interrupted follicle stimulating hormone and added androgen for poor responders—an observational pilot study Frederic Mitri,

Dynamic antimüllerian hormone levels during controlled ovarian hyperstimulation predict in vitro fertilization response and pregnancy outcomes Aaron.

Ultrashort flare gonadotropin-releasing hormone (GnRH) agonist/GnRH antagonist protocol: a valuable tool in the armamentarium of ovulation induction for.

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis

David E. Reichman, M.D., Dan Goldschlag, M.D., Zev Rosenwaks, M.D.

Impact of pituitary suppression on antral follicle count and oocyte recovery after ovarian stimulation Nam D. Tran, M.D., Ph.D., Lusine Aghajanova, M.D.,

Tomer Singer, M. D. , David H. Barad, M. D. , M. S

Comparison of antimüllerian hormone levels and antral follicle count as predictor of ovarian response to controlled ovarian stimulation in good-prognosis.

Treatment of Ovarian Hyperstimulation Syndrome Utilizing a Dopamine Agonist and Gonadotropin Releasing Hormone antagonist N. Rollene, M. Amols, S. Hudson,

Changes in cytokine levels of patients with ovarian endometriosis after treatment with gonadotropin-releasing hormone analogue, ultrasound-guided drainage,

Diminished intrafollicular estradiol levels in in vitro fertilization cycles from women with reduced ovarian response to recombinant human follicle-stimulating.

Efficacy and safety of human chorionic gonadotropin for follicular phase stimulation in assisted reproduction: a systematic review and meta-analysis

Fertility and Sterility

Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series Nanette L. Rollene,

Effectiveness of highly purified human menopausal gonadotropin vs

The serum follicle-stimulating hormone-to-luteinizing hormone ratio at the start of stimulation with gonadotropins after pituitary down-regulation is.

Moderately elevated levels of basal follicle-stimulating hormone in young patients predict low ovarian response, but should not be used to disqualify.

Serum levels of antimüllerian hormone in early maturing girls before, during, and after suppression with GnRH agonist Casper P. Hagen, M.D., Kaspar Sørensen,

Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing.

An investigation into the relationship between the metabolic profile of follicular fluid, oocyte developmental potential, and implantation outcome Martina.

Cost-effectiveness comparison between pituitary down-regulation with a gonadotropin- releasing hormone agonist short regimen on alternate days and an antagonist.

David H. Barad, M.D., M.S., Norbert Gleicher, M.D.

A combined analysis of data to identify predictive factors for spermatogenesis in men with hypogonadotropic hypogonadism treated with recombinant human.

Evaluating the role of exogenous luteinizing hormone in poor responders undergoing in vitro fertilization with gonadotropin-releasing hormone antagonists

Comparing anti-Müllerian hormone (AMH) and follicle-stimulating hormone (FSH) as predictors of ovarian function David H. Barad, M.D., M.S., Andrea Weghofer,

Comparison of a gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare-up regimen in poor responders undergoing ovarian stimulation

Cem Fiçicioǧlu, M. D. , Tayfun Kutlu, M. D. , Elif Baglam, M. D

Early menopause in mothers of children with Down syndrome?

Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles

Microdose gonadotropin-releasing hormone agonist in the absence of exogenous gonadotropins is not sufficient to induce multiple follicle development

A novel “delayed start” protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders Hakan Cakmak, M.D., Nam D. Tran,

A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for.

Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing.

A prospective, comparative analysis of anti-Müllerian hormone, inhibin-B, and three- dimensional ultrasound determinants of ovarian reserve in the prediction.

Comparisons of inhibin B versus antimüllerian hormone in poor ovarian responders undergoing in vitro fertilization Rongrong Tan, M.M.Sc., Danhua Pu,

Day-5 inhibin B serum concentrations and antral follicle count as predictors of ovarian response and live birth in assisted reproduction cycles stimulated.

Presentation transcript:

Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis patients Joan-Carles Arce, M.D., Ph.D., Antonio La Marca, M.D., Ph.D., Bjarke Mirner Klein, Ph.D., Anders Nyboe Andersen, M.D., Richard Fleming, Ph.D. Fertility and Sterility Volume 99, Issue 6, Pages 1644-1653.e1 (May 2013) DOI: 10.1016/j.fertnstert.2012.12.048 Copyright © 2013 American Society for Reproductive Medicine Terms and Conditions

Figure 1 Box and whisker plots for antimüllerian hormone (AMH), follicle-stimulating hormone (FSH), inhibin B, and antral follicle count (AFC) at start of stimulation in patients with various numbers of oocytes retrieved after stimulation with highly purified human menopausal gonadotropin (hphMG) or recombinant FSH in a gonadotropin-releasing hormone (GnRH) antagonist protocol. Values are median (lines), 25th–75th percentile (boxes), and 10th–90th percentile (whiskers). hphMG: ≤3 (n = 47), 4–7 (n = 124), 8–14 (n = 145), 15–19 (n = 38), ≥ 20 (n = 18); recombinant FSH: ≤3 (n = 25), 4–7 (n = 112), 8–14 (n = 147), 15–19 (n = 55), ≥ 20 (n = 30). Fertility and Sterility 2013 99, 1644-1653.e1DOI: (10.1016/j.fertnstert.2012.12.048) Copyright © 2013 American Society for Reproductive Medicine Terms and Conditions

Figure 2 Receiver operating characteristic (ROC) curve analysis showing the predictive values of antimüllerian (AMH), follicle-stimulating hormone (FSH), inhibin B, and antral follicle count (AFC) at start of stimulation for estimation of poor ovarian response (≤3 oocytes retrieved or cycle cancellation due to poor response) and high response (≥15 oocytes retrieved or cycle cancellation due to excessive response), respectively, after controlled ovarian stimulation in patients treated with highly purified human menopausal gonadotropin (hphMG) or recombinant FSH in a gonadotropin-releasing hormone (GnRH) antagonist protocol. The diagonal line is the reference line of no discrimination (area under the curve = 0.5). Fertility and Sterility 2013 99, 1644-1653.e1DOI: (10.1016/j.fertnstert.2012.12.048) Copyright © 2013 American Society for Reproductive Medicine Terms and Conditions